Paolo Tarantino: The largest HER2-low sub-analysis of a RCT led by Guilherme Nader-Marta

Paolo Tarantino shared a recent article by Guilherme Nader-Marta et al. published in Breast Cancer Research. Read his post on X below:

“Clinical characterization, prognostic, and predictive values of HER2-low in patients with early breast cancer in the PALLAS trial (ABCSG-42/AFT-05/BIG-14–13/PrE0109)”

Authors: Guilherme Nader-Marta, Christian Singer, Dominik Hlauschek, Erica Mayer, Michael Gnant et al.

“The largest HER2-low sub-analysis of a RCT (PALLAS) just published in BCR, led by Guilherme Nader-Marta.

HER2-low expression was:

• not prognostic
• not predictive of palbo benefit
• highly heterogenous in prevalence across countries (range 16-75%; p < 0.001).”

More posts featuring Paolo Tarantino.

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.